Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations
Authors:
- Gary T. FergusonGFGary T. Ferguson
- Antonio AnzuetoAAAntonio Anzueto
- Richard FeiRFRichard Fei
- Amanda EmmettAEAmanda Emmett
- Katharine KnobilKKKatharine Knobil
- Christopher KalbergCKChristopher Kalberg
- 1 August 2008
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 102 (8) , 1099-1108
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Risk Indexes for Exacerbations and Hospitalizations Due to COPDChest, 2007
- Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax, 2005
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Impact of preventing exacerbations on deterioration of health status in COPDEuropean Respiratory Journal, 2004
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002
- Lower Respiratory Illnesses Promote FEV1 Decline in Current Smokers But Not Ex-Smokers with Mild Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998